Mary J. Fidler

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet · 2015 · 6.4K citations

Pembrolizumab Versus Docetaxel, Oncology, Clinical Trials +7

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

Shirish M. Gadgeel, Nathan A. Pennell, Mary J. Fidler et al. · Journal of Thoracic Oncology · 2018 · 222 citations · Full text

Medicine, Immunology, Maintenance Pembrolizumab +7

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

Jenna H. Newman, Charles B. Chesson, Nora L. Herzog et al. · Proceedings of the National Academy of Sciences · 2019 · 185 citations · Full text

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6